Botensilimab, an Fc-Enhanced Anti-CTLA-4 Antibody, Is Effective against Tumors Poorly Responsive to Conventional Immunotherapy.

Authors :: Chand D
Savitsky DA
Krishnan S
Mednick G
Delepine C
Garcia-Broncano P
Soh KT
Wu W
Wilkens MK
Udartseva O
Vincent S
Joshi B
Keith JG
Manrique M
Marques M
Tanne A
Levey DL
Han H
Ng S
Ridpath J
Huber O
Morin B
Galand C
Bourdelais S
Gombos RB
Ward R
Qin Y
Waight JD
Costa MR
Sebastian-Yague A
Rudqvist NP
Pupecka-Swider M
Venkatraman V
Slee A
Patel JM
Grossman JE
Wilson NS
Von Hoff DD
Stebbing J
Curiel TJ
Buell JS
O'Day SJ
Stein RB
Source :: Cancer discovery [Cancer Discov] 2024 Dec 02; Vol. 14 (12), pp. 2407-2429.
Publication Year :: 2024
Abstract: Significance: This study reveals that Fc-enhanced anti-CTLA-4 harnesses novel mechanisms to overcome the limitations of conventional anti-CTLA-4, effectively treating poorly immunogenic and treatment-refractory cancers. Our findings support the development of a new class of immuno-oncology agents, capable of extending clinical benefit to patients with cancers resistant to current immunotherapies.<br /> (©2024 The Authors; Published by the American Association for Cancer Research.)

Subjects :: Humans
Mice
Animals
Neoplasms drug therapy
Neoplasms immunology
Neoplasms therapy
Antibodies, Monoclonal, Humanized therapeutic use
Cell Line, Tumor
Antibodies, Monoclonal therapeutic use
Antibodies, Monoclonal pharmacology
Immunoglobulin Fc Fragments therapeutic use
CTLA-4 Antigen antagonists & inhibitors
Immunotherapy methods

Full Text Access

Tools